The difference in vessel density measurements obtained after anti-VEGF therapy may underestimate the initial extent of capillary dropout, as treatment can improve capillary visibility and, in certain cases, induce partial reperfusion, particularly in patients without diabetic macular edema. This evidence concerns the gene VEGFA and diabetic macular edema.